GlassScriptPhysician profile
Bridget M Rossi
NPI 1023615440
$1,707.38
in general payments reported to CMS, 2019-2025
24 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $579 · 2022: $125 · 2023: $436 · 2024: $409 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $258.61 | 2022-2025 | Rybrevant, Darzalex, Balversa |
| Novartis Pharmaceuticals Corporation | $239.64 | 2023-2025 | |
| Glaxosmithkline, LLC. | $156.98 | 2021-2024 | Ojjaara, Jemperli, Zejula |
| Ibsa Pharma INC. | $125.00 | 2021 | |
| Genzyme Corporation | $120.27 | 2021-2024 | |
| Puma Biotechnology, INC. | $116.26 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $103.99 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $100.61 | 2021-2024 | Enhertu, Calquence, Imfinzi |
| Merck Sharp & Dohme LLC | $93.45 | 2023 | Keytruda, Lynparza |
| Incyte Corporation | $52.59 | 2023-2025 | Monjuvi, Pemazyre |
| Pfizer INC. | $47.70 | 2024-2025 | |
| Eisai INC. | $38.88 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $31.10 | 2021 | |
| Daiichi Sankyo INC. | $29.77 | 2024 | Enhertu |
| Beigene USA, INC. | $27.33 | 2024 | Brukinsa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $23.95 | 2023 | Orserdu |
| Karyopharm Therapeutics INC. | $23.47 | 2023 | Xpovio |
| Jazz Pharmaceuticals INC. | $20.37 | 2024 | |
| Rigel Pharmaceuticals, INC. | $18.11 | 2023 | Tavalisse, Rezlidhia |
| Azurity Pharmaceuticals, INC. | $17.61 | 2024 | Vivimusta |
| Astellas Pharma US INC | $17.17 | 2023 | Padcev |
| Amgen INC. | $16.30 | 2023 | Lumakras |
| Ipsen Biopharmaceuticals, INC | $14.43 | 2024 | Onivyde, Somatuline Depot |
| Lilly USA, LLC | $13.79 | 2024 | Jaypirca, Retevmo, Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.